Given the interest in my recent response to Broadbent about whether our immune system will get better after treatment: healthunlocked.com/cllsuppo... , I coincidentally came across this recent paper on Lenalidomide/Revlimid, where unusually for CLL treatment (along with Ibrutinib), immunoglobulin levels increased after treatment : link.springer.com/article/1...
In a recent article published in the Annals of Hematology, researchers from China reported the results of a literature review and meta-analysis that evaluated the response to lenalidomide in 559 patients with relapsed or refractory CLL.
* Lenalidomide administered alone showed only a modest response in patients, with an overall response rate (ORR) of 24.4% and a complete response (CR) of only 3%
* A significantly higher response was noted in patients who received lenalidomide plus an anti-CD20 monoclonal antibody, with an ORR of 60% and a CR of 13%
Some historical background from the CLL Updates 2011: updates.clltopics.org/3728-...
Now for some very encouraging news: as most of you know, CLL patients are prone to low immunoglobulin levels and these levels drop as the disease progresses. Low immunoglobulin levels are one reason why our guys are more prone to infections. Lenalidomide therapy seems to be unique in reversing this trend in immunoglobulin levels. In patients who finished at least 15 cycles of therapy, immunoglobulin levels increased across all Ig classes (IgG, IgA and IgM).
Subsequently 'The U.S. Food and Drug Administration (FDA) halted a clinical trial of the anti-cancer drug Revlimid (lenalidomide) because of significant safety concerns. The ORIGIN trial (NCT00910910), which was evaluating Revlimid treatment for a new use as an initial therapy for chronic lymphocytic leukemia (CLL) in patients 65 years and older, showed higher rates of death in patients treated with Revlimid compared to those treated with chlorambucil.' : fda.gov/Drugs/DrugSafety/uc...
So the search for a treatment that controls or eliminates CLL and restores our immune system continues...
Neil